Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Reyataz To Launch In July; Lipid Data Included In Labeling

Executive Summary

Bristol-Myers Squibb will make Reyataz (atazanavir) available in July following the June 20 approval of the HIV treatment
Advertisement

Related Content

Kaletra Scripts Outpace Sales; Abbott Expects 10% Sales Growth
Kaletra Scripts Outpace Sales; Abbott Expects 10% Sales Growth
Bristol Reyataz Dosing For Renally-Impaired Patients Will Be Phase IV Study
Bristol Reyataz Dosing For Renally-Impaired Patients Will Be Phase IV Study
HIV Market: Reyataz Races To 10% Market Share, Fuzeon Building Steadily
HIV Market: Reyataz Races To 10% Market Share, Fuzeon Building Steadily
HIV Treatment Guidelines Give Kaletra Timely Boost As Reyataz Launches
Bristol Reyataz Gets Broad Label Vote Despite Concerns In Drug Experienced
Bristol Reyataz Gets Broad Label Vote Despite Concerns In Drug Experienced
Reyataz Lipid Effect Offers Benefit But Not In Lipodystrophy, Cmte. Says
Advertisement
UsernamePublicRestriction

Register

PS041991

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel